Cormorant Asset Management, LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Cormorant Asset Management, LP disclosed 48 US equity positions worth $1.8bn in its Q4 2024 13F filing. The largest position was MLTX at 25.3% of the reported book, followed by PRAX and JANX. Against the Q3 2024 filing, it opened 8 new positions, added to 7 and reduced 11 among the top 48 holdings.
What did Cormorant Asset Management, LP own in Q4 2024? Top 48 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 25.3% | $460.0m | 8,494,151 | 0% | held |
| 2 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 7.2% | $130.3m | 1,693,219 | 95% | added |
| 3 | JANX JANUX THERAPEUTICS INC | Healthcare | 6.2% | $112.4m | 2,100,000 | 100% | added |
| 4 | ACLXGBX ARCELLX INC | 5.5% | $99.7m | 1,300,000 | 4% | added | |
| 5 | EWTX EDGEWISE THERAPEUTICS INC | 5.0% | $91.0m | 3,406,534 | 0% | held | |
| 6 | NEWAMSTERDAM PHARMA COMPANY | 4.6% | $83.5m | 3,250,000 | 32% | added | |
| 7 | EYPT EYEPOINT PHARMACEUTICALS INC | Healthcare | 3.4% | $62.0m | 8,325,000 | 0% | held |
| 8 | RAPP RAPPORT THERAPEUTICS INC | 2.9% | $52.2m | 2,940,921 | 0% | held | |
| 9 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 2.8% | $51.1m | 1,000,000 | -9% | reduced | |
| 10 | INSM INSMED INC | Healthcare | 2.5% | $44.9m | 650,000 | 30% | added |
| 11 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 2.4% | $43.9m | 1,600,000 | -14% | reduced |
| 12 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.4% | $42.9m | 2,561,600 | 0% | held | |
| 13 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 2.1% | $38.2m | 1,059,331 | – | new |
| 14 | PCVX VAXCYTE INC | Healthcare | 1.9% | $34.8m | 425,000 | -57% | reduced |
| 15 | MERUS N V | 1.7% | $31.1m | 740,000 | 0% | held | |
| 16 | HELIX ACQUISITION CORP II | 1.7% | $30.5m | 2,909,000 | 0% | held | |
| 17 | RNAGBP AVIDITY BIOSCIENCES INC | 1.7% | $30.5m | 1,050,000 | 0% | held | |
| 18 | PHVS PHARVARIS N V | 1.5% | $28.1m | 1,466,460 | 0% | held | |
| 19 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.5% | $28.0m | 2,375,000 | 0% | held |
| 20 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 1.5% | $27.7m | 500,000 | 0% | held |
| 21 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.5% | $27.5m | 325,000 | -19% | reduced |
| 22 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.4% | $25.4m | 1,825,000 | -22% | reduced |
| 23 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.2% | $22.4m | 400,000 | 0% | held |
| 24 | CGON CG ONCOLOGY INC | Healthcare | 1.2% | $22.2m | 775,000 | -21% | reduced |
| 25 | CRGX CARGO THERAPEUTICS INC | 0.9% | $17.1m | 1,182,563 | 0% | held | |
| 26 | ALMS ALUMIS INC | 0.9% | $16.9m | 2,147,396 | 0% | held | |
| 27 | OKUR ONKURE THERAPEUTICS INC | 0.9% | $15.8m | 1,837,739 | – | new | |
| 28 | AVBP ARRIVENT BIOPHARMA INC | 0.9% | $15.6m | 585,462 | 0% | held | |
| 29 | ABVX ABIVAX SA | 0.9% | $15.6m | 2,130,000 | 0% | held | |
| 30 | ENGENE HOLDINGS INC | 0.8% | $15.5m | 2,323,595 | 132% | added | |
| 31 | BIOA BIOAGE LABS INC | 0.8% | $15.2m | 2,629,529 | 61% | added | |
| 32 | BMEA BIOMEA FUSION INC | 0.8% | $13.9m | 3,570,872 | 0% | held | |
| 33 | MBX MBX BIOSCIENCES INC | Healthcare | 0.7% | $12.9m | 700,000 | 0% | held |
| 34 | SEPN SEPTERNA INC | 0.7% | $12.8m | 560,000 | – | new | |
| 35 | IBRX IMMUNITYBIO INC | 0.4% | $7.7m | 3,000,000 | – | new | |
| 36 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.3% | $5.6m | 250,000 | – | new |
| 37 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 0.3% | $5.3m | 500,000 | – | new |
| 38 | MNLOUSD VYNE THERAPEUTICS INC | 0.3% | $4.7m | 1,394,336 | 0% | held | |
| 39 | KALA KALA BIO INC | 0.2% | $4.2m | 603,027 | – | new | |
| 40 | GHRS GH RESEARCH PLC | 0.2% | $4.2m | 593,043 | 0% | held | |
| 41 | YMABUSD Y-MABS THERAPEUTICS INC | 0.2% | $3.3m | 425,000 | -71% | reduced | |
| 42 | URGN UROGEN PHARMA LTD | Healthcare | 0.2% | $3.2m | 300,000 | -81% | reduced |
| 43 | OMER OMEROS CORP | 0.2% | $3.0m | 300,000 | – | new | |
| 44 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.2% | $2.8m | 254,161 | -41% | reduced |
| 45 | BHVN BIOHAVEN LTD | Healthcare | 0.1% | $2.1m | 55,539 | -86% | reduced |
| 46 | VERVE THERAPEUTICS INC | 0.1% | $2.0m | 350,000 | 0% | held | |
| 47 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.1% | $1.0m | 103,633 | 0% | held | |
| 48 | RAPT THERAPEUTICS INC | 0.0% | $316.0k | 200,000 | -60% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.